Symposia and Workshops

Symposium and Workshop Sessions are three hours each and Mini Symposia are scheduled for 75 minutes each.

Symposia and Workshops are scheduled for Monday, November 17, from 9:00 am to 12:00 noon and in the afternoon from 2:00 pm to 5:00 pm; Tuesday, November 18, from 9:00 am to 12:00 noon and in the afternoon from 2:00 pm to 5:00 pm; and Wednesday, November 19, from 9:00 am to 12:00 noon and in the afternoon from 2:00 pm to 5:00 pm. Mini Symposia are scheduled for Wednesday, November 19, in the afternoon from 2:00 pm to 5:00 pm. Times listed are in Mountain Standard Time.

The following learning levels have been identified for ACT educational offerings.

Below are the titles of the Symposia/Workshop sessions to be presented at this year’s Annual Meeting. Detailed information about each session will be shared in April.

• Advancing Nitrosamine Risk Assessment for Human Health Risk Assessment.
• Antibody-Drug Conjugate (ADC) Nonclinical Safety: Background, Challenges, and Mitigation Strategies
• Balancing Innovation and Caution: Artificial Intelligence (AI) and Machine Learning (ML) in Toxicology
• Consulting Is a Viable Career Path: How to Start and Build a Career as a Toxicology Consultant
• Developing Predictive Models to Facilitate Interpretation of Toxicology Study Results
• From Bench to Birth: Navigating DART Challenges in Next Generation Therapeutics
• Harnessing Complex New Approach Methodologies (NAMs) to Tackle Discovery Toxicology Challenges
• Hot Topics
• Impurity Limits and Approaches for Endogenous Substances Commonly Identified in Biologic Therapeutics
• Navigating the Frontier of Science and Regulation: Exploring the Latest Breakthroughs in New Approach Methodologies
• Nonclinical Considerations for the Development of Radiopharmaceuticals
• Nose to the Grindstone: Intranasal Therapies
• Oligonucleotide-Based Therapeutics, Hybridization-Dependent Off-Target Effects, and Impacts on Nonclinical Safety Packages
• Optimize Your FDA Interactions: An Industry and FDA Perspective
• Predicting Adversities in New Modalities: Lessons Learned from Clinical and Preclinical in Cell and Gene Therapies
• Strategic Use of Transgenic Mice or Surrogate Molecules in DART Studies to Support Biologic Drug Development: Recent Success/Failure
• Toxicologic Assessment of Psychoactive/Psychedelic Drugs: Disentangling CNS Pharmacology and Toxicity
• Transitioning to the New ICH M12 Guideline on Drug-Drug Interactions: Concepts and Implications
• What to Do When Things Go Wrong: Perspectives from Early Career Experts on Navigating Unexpected Situations
• When to Waive: Balancing Risk and Flexibility in Nonclinical Safety Studies